Bharat Biotech’s Covaxin Set for Trials on Children

No Comments
Posted in Featured, National, Northeast

Bharat Biotech was on Tuesday recommended by an expert panel has allowed to send its COVID-19 vaccine ‘Covaxin’ for phase II and phase III clinical trials on children between the age of two and 18 years.

An approval to vaccinate the younger population would be a major breakthrough as it would mean reopening of schools and normal classes.

The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) deliberated upon Hyderabad-based Bharat Biotech’s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.

The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur, officials said.

Tags: , ,

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

More Articles